Why small biotechs stand to benefit most — and what the market signals actually say. Agrowing number of life sciences organizations are turning to fractional leaders: senior executives who work on a part-time or interim basis to fill critical commercialization gaps quickly and cost-effectively.

Focused and durable foundations for biotech growth — why programs underperform, what success actually looks like, and three principles that separate the two.